Superworth

Denali Therapeutics price to free cash flow DNLI

Market value divided by free cash flow over the last twelve months, since 2019.

Today, Nov 2, 2026
n/m
not a meaningful number
Last meaningful
11.2×
Feb 2022
8-year median
16.0×
8-year range
10.9× to 56.9×
Peer median
30.2×

Denali Therapeutics' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Feb 2022, at 11.2×.

On the days it had one over the last 8 years, its median was 16.0×, from 10.9× in Jan 2022 to 56.9× in Apr 2019.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
202211.2×10.9×14.0×
202115.1×13.7×22.5×
2020n/m a value too high to mean anything
201950.2×39.7×56.9×

Against its peers

Companies in Biotechnology nearest Denali Therapeutics' size, closest first, today.

CompanyPrice to free cash flow
DNLIDenali Therapeuticsn/m
ADMAAdma Biologics21.3×
VCELVericel33.6×
KRYSKrystal Biotech34.0×
RGENRepligen87.2×
MGTXMeiraGTx85.5×
TECHBIO-TECHNE43.3×
HALOHalozyme Therapeutics18.2×
NBIXNeurocrine Biosciences17.0×
EXELExelixis14.8×
ALNYAlnylam Pharmaceuticals26.7×
Peer median30.2×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Denali Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.